In short
This article discusses a clinical trial investigating the long-term safety of Satoreotide Tetraxetan Lutetium-177 (177Lu-IPN01072) in patients with somatostatin receptor-positive neuroendocrine tumors (NETs). The study aims to evaluate the occurrence of secondary cancers and overall survival in patients who have previously received this treatment in an Ipsen-sponsored clinical study.
At a glance
- Study Type
- Long-term safety surveillance study
- Drug Name
- Satoreotide Tetraxetan Lutetium-177 (177Lu-IPN01072)
- Condition Studied
- Somatostatin Receptor Positive Neuroendocrine Tumors (NETs)
- Main Objective
- Assess incidence of second primary malignancies
- Secondary Objectives
- Evaluate long-term safety profile and overall survival
- Inclusion Criteria
- Previous treatment with 177Lu-IPN01072 in Study OPS-C-001
- Exclusion Criteria
- None specified
- Primary Endpoint
- Presence of second primary malignancies
- Secondary Endpoints
- Treatment-related adverse events, changes in laboratory tests, overall survival
- Maximum Treatment Period
- 36 months
- Maximum Dose
- 7.4 GBq per day, 3 GBq total
- Administration Route
- Intravenous
What is SATOREOTIDE TETRAXETAN LUTETIUM-177?
SATOREOTIDE TETRAXETAN LUTETIUM-177 is an innovative medical treatment that is currently being studied for its potential in treating certain types of cancer. This compound is also known by several other names, including: 177Lu-SSO110 Lutetium-177 DOTA Satoreotide OPS201 Lu-177 OPS-201 These alternative names may be used interchangeably in medical literature or discussions with healthcare providers.
What Medical Condition Does It Treat?
SATOREOTIDE TETRAXETAN LUTETIUM-177 is being investigated for the treatment of Somatostatin Receptor Positive Neuroendocrine Tumors (NETs). Neuroendocrine tumors are a type of cancer that begins in specialized cells called neuroendocrine cells. These cells have traits similar to both nerve cells and hormone-producing cells, and are found throughout the body.
How Does It Work?
While the exact mechanism is not fully detailed in the provided information, we can infer some details based on the drug's composition and target: Targeted Approach: The drug targets somatostatin receptors, which are often overexpressed in neuroendocrine tumors. This allows for a more focused treatment approach. Radioactive Component: The "Lutetium-177" in the drug's name indicates that it contains a radioactive isotope. This suggests it may work through targeted radiation therapy, delivering radiation directly to cancer cells. Peptide Receptor Radionuclide Therapy (PRRT): Based on its composition, this drug likely falls under the category of PRRT, a type of treatment that combines a targeting molecule (peptide) with a radioactive material. This approach allows the drug to specifically target and potentially destroy cancer cells while minimizing damage to healthy tissues.
Current Clinical Study
A clinical study is currently underway to evaluate the long-term safety of SATOREOTIDE TETRAXETAN LUTETIUM-177. This study, identified as "2024-515071-35-00", has the following key features: Study Type: It is a multicentre surveillance study, meaning it's being conducted at multiple medical centers to gather more comprehensive data. Main Objective: To assess the incidence of second primary haematological and non-haematological malignancies in patients who have received this treatment. Secondary Objectives: To evaluate the long-term safety profile of the drug To evaluate overall survival of patients who have received the treatment Eligibility: Participants must have received at least one infusion of 177Lu-IPN01072 in a previous study (OPS-C-001) and be capable of giving informed consent. This study aims to provide crucial information about the long-term effects and safety of this treatment.
How Is It Administered?
SATOREOTIDE TETRAXETAN LUTETIUM-177 is administered as a solution for infusion. This means it is given intravenously (directly into a vein). The drug is measured in units called gigabecquerels (GBq), which is a measure of radioactivity. The maximum daily dose is 7.4 GBq The maximum total dose over the course of treatment is 3 GBq The maximum treatment period is 36 months It's important to note that these are maximum amounts, and the actual dose given to a patient may be lower, depending on individual factors determined by the healthcare team.
Safety Profile and Monitoring
The ongoing clinical study is focused on assessing the long-term safety of SATOREOTIDE TETRAXETAN LUTETIUM-177. Key aspects of safety monitoring include: Second Primary Malignancies: The study is closely monitoring for the development of new cancers that might be related to the treatment. Adverse Events: Researchers are tracking any side effects or complications that may be related to the treatment. Laboratory Tests: Regular blood tests are being conducted to monitor changes in haematology (blood cells) and biochemistry (organ function). Long-term Follow-up: Patients are being followed over an extended period to understand the long-term effects of the treatment. This comprehensive monitoring helps ensure patient safety and provides valuable data on the long-term effects of the treatment.
Potential Benefits
While the study is primarily focused on safety, it also aims to evaluate the overall survival of patients who have received SATOREOTIDE TETRAXETAN LUTETIUM-177. This suggests that the treatment may have the potential to extend life in patients with somatostatin receptor positive neuroendocrine tumors. It's important to note that as this is an ongoing study, the full benefits and risks of the treatment are still being evaluated. Patients considering this treatment should discuss the potential benefits and risks thoroughly with their healthcare provider.